Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon and ribavirin plus deferasirox in transfusion-dependent beta-thalassemia with chronic hepatitis C
2012-000955-15Phase 2Completed
- Sponsor
- AOU Policlinico di Modena
- Start
- Sep 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and deferasirox in hepatitis C virus infection, beta thalassemia and transfusional hemosiderosis, sponsored by AOU Policlinico di Modena. Primary endpoint: Incidence, type and severity of serious adverse events in first 12 weeks. Started Sep 2012; status: completed.
02
Drugs
peginterferon alfa-2apeginterferon alfa-2bribavirindeferasirox
03
Conditions
hepatitis C virus infectionbeta thalassemiatransfusional hemosiderosis
Beyond the preview
Go deeper on 2012-000955-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000955-15.